BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
81.99
-0.08 (-0.10%)
Aug 5, 2026, 4:00 PM EDT - Market closed
BridgeBio Pharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -729.89 | -732.94 | -543.35 | -653.25 | -484.65 | -586.45 |
Depreciation & Amortization | 5.34 | 5.43 | 6.08 | 6.49 | 6.77 | 5.84 |
Stock-Based Compensation | 140.38 | 133.02 | 95.8 | 108.71 | 91.56 | 99.51 |
Other Adjustments | 84.55 | 199.63 | -111.3 | 5.27 | -61.25 | -12.43 |
Change in Receivables | -89.96 | -134.72 | -2.97 | 15.33 | 15.17 | -19.75 |
Changes in Inventories | -29.17 | -25.31 | - | - | - | - |
Changes in Accounts Payable | 1.87 | 26.61 | 1.51 | 2.78 | -0.35 | 2.83 |
Changes in Accrued Expenses | 25.71 | 108 | 29.9 | 1.46 | -14.4 | 32.72 |
Changes in Unearned Revenue | -11.24 | -11.43 | 21.88 | -5.44 | 15.26 | - |
Changes in Other Operating Activities | 18.37 | -14.21 | -18.28 | -9.08 | 12.4 | -20.2 |
Operating Cash Flow | -443.95 | -445.91 | -520.73 | -527.72 | -419.49 | -497.93 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Capital Expenditures | -1.17 | -1.1 | -0.93 | -1.31 | -4.82 | -13.25 |
Purchases of Intangible Assets | -6.9 | -8.5 | -7.98 | - | -1.5 | -35 |
Purchases of Investments | -80.86 | -28.2 | -114.08 | -137.26 | -193.06 | -643.28 |
Proceeds from Sale of Investments | - | 13.3 | 183.91 | 193.11 | 532.52 | 477.04 |
Other Investing Activities | - | - | -0.14 | -0.5 | 120 | 13.65 |
Investing Cash Flow | -65.63 | -24.49 | 60.78 | 54.03 | 453.15 | -200.83 |
Long-Term Debt Issued | 332.5 | 575 | 950 | - | - | 1,204 |
Long-Term Debt Repaid | -26.61 | -474.46 | -473.42 | - | -20.49 | -124.12 |
Net Long-Term Debt Issued (Repaid) | 305.89 | 100.54 | 476.58 | - | -20.49 | 1,080 |
Issuance of Common Stock | 56.45 | 34.15 | 322.9 | 459.22 | 8.08 | 20.46 |
Repurchase of Common Stock | -99.02 | -62.5 | -7.53 | -6.88 | -1.56 | -204.75 |
Net Common Stock Issued (Repurchased) | -42.58 | -28.35 | 315.37 | 452.34 | 6.52 | -184.28 |
Other Financing Activities | -9.43 | 287.11 | -43.5 | -0.8 | 0.84 | -158.95 |
Financing Cash Flow | 848.86 | 359.29 | 748.46 | 451.54 | -13.13 | 736.45 |
Net Cash Flow | 339.28 | -111.1 | 288.51 | -22.15 | 20.52 | 37.69 |
Free Cash Flow | -445.12 | -447.01 | -521.66 | -529.03 | -424.32 | -511.18 |
Free Cash Flow Growth | - | - | - | - | - | - |
FCF Margin | -76.75% | -89.03% | -235.08% | -5686.62% | -546.46% | -733.23% |
Free Cash Flow Per Share | -2.31 | -2.33 | -2.80 | -3.25 | -2.88 | -3.54 |
Levered Free Cash Flow | -405.95 | -536.4 | -19.02 | -648.29 | -486.81 | 525.09 |
Unlevered Free Cash Flow | -515.28 | -435.73 | -554.08 | -612.45 | -497.34 | -568.68 |